Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to tr... Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to treat a rare monogenic muscle disease. 詳細を表示
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, Dec. 20, 2024 SAN DIEGO, Dec. 20, 2024 /PRNewswire/ -- Avidity Biosciences, Inc...
Avidity Biosciences to Participate in Upcoming Investor Conference PR Newswire SAN DIEGO, Nov. 26, 2024 SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, Nov. 21, 2024 SAN DIEGO, Nov. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.79 | -5.32579589408 | 33.61 | 34.78 | 30.07 | 1656419 | 31.95957227 | CS |
4 | -10.74 | -25.234962406 | 42.56 | 45.98 | 30.07 | 1260250 | 36.92482601 | CS |
12 | -10.57 | -24.935126209 | 42.39 | 56 | 30.07 | 1087400 | 42.69039529 | CS |
26 | -6.24 | -16.3951655281 | 38.06 | 56 | 30.07 | 1307362 | 43.00008809 | CS |
52 | 22.76 | 251.214128035 | 9.06 | 56 | 8.37 | 1266992 | 33.33563102 | CS |
156 | 8.65 | 37.3327578766 | 23.17 | 56 | 4.825 | 1018607 | 22.06642835 | CS |
260 | 5.32 | 20.0754716981 | 26.5 | 56 | 4.825 | 767811 | 22.44942189 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約